Wednesday, June 19, 2013 Last update: 12:45 AM
Company Tech News as it Breaks
R-Tech Ueno, Ltd.
News articles for R-Tech Ueno, Ltd.:
Sunday, May 19, 2013
- R-Tech Ueno: Start of the Patient Enrollment of a Phase I/II Clinical Study of Recombinant Human Serum Albumin-Containing Ophthalmic Solution (Development Code: RU-101) in US for the Treatment of SeveR-Tech Ueno, Ltd. (JASDAQ:4573): This is to announce start of the patient enrollment of the first stage ... read more
Thursday, April 25, 2013
- R-Tech Ueno Receives FDA IND Approval for RU-101 (r-HSA) to Treat Severe Dry EyeR-Tech Ueno (JASDAQ: 4573): This is to announce that we have submitted IND(Note1) application to ... read more
Sunday, March 17, 2013
- R-Tech Ueno: Start of the Patient Enrollment of a Phase 3 Clinical Study of Unoprostone (Development Code UF-021) Ophthalmic Solution for the Treatment of Retinitis PigmentosaR-Tech Ueno (JASDAQ:4573) is pleased to announce the start of the patient enrollment of a Phase 3 clinical study with Unoprostone(note 1) (development code UF-021) ophthalmic solution that ... read more
Wednesday, February 20, 2013
- R-Tech Ueno: Announcement of Commercial Availability of RESCULA® Eye Drops in the U.S. MarketR-Tech Ueno (JASDAQ:4573): Sucampo Pharmaceuticals, Inc. (hereinafter referred to as "Sucampo") announced that RESCULA® Eye ... read more
Monday, February 11, 2013
- R-Tech Ueno: Lawsuit Claiming Infringement of AMITIZA® Capsules PatentsR-Tech Ueno (JASDAQ: 4573): Sucampo Pharmaceuticals, Inc. ("Sucampo") announced that it, together with R-Tech Ueno, ... read more